SCHEMBL1697256

SCHEMBL1697256

FC(Br)CCl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3097804 0.73
SCHEMBL11583876 0.72
SCHEMBL728388 0.70
SCHEMBL313208 0.70
SCHEMBL14127604 0.70
SCHEMBL23710645 0.68
SCHEMBL1038664 0.67
SCHEMBL5439701 0.67
SCHEMBL1040886 0.67
SCHEMBL1647946 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2585449-A1 PROCESS FOR THE PREPARATION OF 5-SUBSTITUTED 1-ALKYLTETRAZOLYL OXIME DERIVATIVES Bayer Intellectual Property GmbH (DE) 2013-05-01 EP disclosed
WO-2012000918-A1 PROCESS FOR THE PREPARATION OF 5-SUBSTITUTED 1-ALKYLTETRAZOLYL OXIME DERIVATIVES BAYER CROPSCIENCE AG (DE) 2012-01-05 WO disclosed
EP-2089023-A2 METHODS OF TREATING NEUROPATHIC PAIN WITH AGONISTS OF PPAR-GAMMA Aestus Therapeutics, Inc. (US) 2009-08-19 EP disclosed
EP-2089017-A2 METHODS OF TREATING NEUROPATHIC PAIN BY MODULATION OF GLYCOGENOLYSIS OR GLYCOLYSIS PATHWAYS Aestus Therapeutics, Inc. (US) 2009-08-19 EP disclosed
WO-2008063842-A2 METHODS OF TREATING NEUROPATHIC PAIN WITH AGONISTS OF PPAR-GAMMA AESTUS THERAPEUTICS, INC. (US) 2008-05-29 WO disclosed
WO-2008057933-A2 METHODS OF TREATING NEUROPATHIC PAIN BY MODULATION OF GLYCOGENOLYSIS OR GLYCOLYSIS PATHWAYS AESTUS THERAPEUTICS, INC. (US) 2008-05-15 WO disclosed